Protection against ionising radiation and synergism with thiols by zinc aspartate.
Pre-treatment with zinc aspartate protected mice against the lethal effects of radiation and raised the LD50 from 8 Gy to 12.2 Gy. Zinc chloride and zinc sulphate were clearly less active. The radioprotective effect of zinc aspartate was equivalent to cysteamine and slightly inferior to S,2-aminoethylisothiourea (AET). Zinc aspartate displayed a similar therapeutic index to the thiols but could be applied at an earlier time before irradiation. Synergistic effects occurred with the combined administration of zinc aspartate and thiols. By giving zinc aspartate with cysteamine, the LD50 was increased to 13.25 Gy and, by combining it in the optimal protocol with AET, to 17.3 Gy. The radioprotection by zinc and its synergism with thiols is explained by the stabilisation of thiols through the formation of zinc complexes.
D000818:Animals; D001224:Aspartic Acid / Q000494:pharmacology*; D002712:Chlorides; D004307:Dose-Response Relationship, Radiation; D004357:Drug Synergism; D005260:Female; D051379:Mice; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D013431:Sulfates / Q000494:pharmacology; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D014916:Whole-Body Irradiation; D015032:Zinc / Q000494:pharmacology; D017967:Zinc Compounds; D019287:Zinc Sulfate
D002712:Chlorides; D011837:Radiation-Protective Agents; D013431:Sulfates; D013438:Sulfhydryl Compounds; D017967:Zinc Compounds; D001224:Aspartic Acid; D019287:Zinc Sulfate; C016837:zinc chloride; D015032:Zinc